Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Knockout Engineered T Cells for Advanced Gastric Adenocarcinoma
ChiCTR-OIC-16009722Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Nov 2016
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PD-1 knockout engineered T cells in gastric adenocarcinoma, sponsored by The First Affiliated Hospital of USTC. Primary endpoint: Safety and tolerability of PD-1 knockout T cells. Started Nov 2016; status: recruiting.
02
Drugs
PD-1 knockout engineered T cells
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on ChiCTR-OIC-16009722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-16009722.